TCEB3 is Regulated by Circ-0000212/miR-140-3p Axis to Promote the Progression of Cervical Cancer

Wang, Yufeng; Miao, Chuan-Hui; Gao, Xiang

doi:10.2147/ott.s278710

Cited by 9 publications

(10 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the same time, more and more studies have shown that circRNA plays a key role in cervical cancer tumorigenesis. In this study, circ_0000212 was enhanced in cervical cancer, consistent with the study of Wang et al [28]. As we have seen, the Cancer Genome Atlas (TCGA) database also exhibited that circ-0000212 expression was upregulated in cervical cancer tissues [28].…”

Section: Discussionsupporting

confidence: 91%

“…In this study, circ_0000212 was enhanced in cervical cancer, consistent with the study of Wang et al [28]. As we have seen, the Cancer Genome Atlas (TCGA) database also exhibited that circ-0000212 expression was upregulated in cervical cancer tissues [28]. In addition, circ_0000212 has been implied to facilitate cell proliferation in colorectal cancer [16].…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Circular RNA circ_0000212 accelerates cervical cancer progression by acting as a miR-625-5p sponge to upregulate PTP4A1

Zheng

Wan

et al. 2022

Anti-Cancer Drugs

View full text Add to dashboard Cite

Cervical cancer is one of the most common malignant tumors in women. Circular RNA (circRNA) has been shown to play a crucial role in cervical cancer. Here, the aim of this study was to explore the functions and a novel miRNA/mRNA network underlying circ_0000212 in cervical cancer regulation. The expression of circ_000212, miR-625-5p and Protein Tyrosine Phosphatase 4A1 (PTP4A1) mRNA was measured by quantitative real-time PCR (qRT-PCR). 5-ethynyl-2’-deoxyuridine assay was conducted to detect the proliferation of cervical cancer cells. Wound healing and transwell assays were employed to assess cell migration and invasion. The angiogenesis abilities of cervical cancer cells were evaluated by tube formation assay. Flow cytometry was performed for analyzing cell apoptosis. The expression of PTP4A1 protein and apoptosis-relative protein were detected via western blot. The dual-luciferase reporter and RNA immunoprecipitation (RIP) assays were employed to clarify the interaction between circ_0000212 or PTP4A1 and miR-625-5p. The impact of circ_0000212 on cervical cancer growth in vivo was detected by xenograft assay. Circ_0000212 and PTP4A1 were highly expressed and miR-625-5p expression level was decreased in cervical cancer. Circ_0000212 silencing suppressed cervical cancer cell proliferation, migration, invasion and angiogenesis while promoting apoptosis. MiR-625-5p was targeted by circ_0000212, and miR-625-5p inhibition reversed the effects of circ_0000212 knockdown. MiR-625-5p directly targeted PTP4A1, and the inhibitory effect of miR-625-5p on the malignant progression of cervical cancer was reversed after PTP4A1 overexpression. In-vivo assays validated that circ_0000212 promoted cervical cancer tumor growth in vivo. circ_0000212 acted as an oncogene in cervical cancer progression, and knockdown of circ_0000212 repressed cervical cancer development by increasing miR-625-5p and decreasing PTP4A1.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 90%

Circular RNA circ_0000212 accelerates cervical cancer progression by acting as a miR-625-5p sponge to upregulate PTP4A1

Zheng

Wan

et al. 2022

Anti-Cancer Drugs

View full text Add to dashboard Cite

show abstract

“…Functionally, we revealed the growth‐ and metastasis‐promoting role of ELOA, supporting ELOA as a candidate oncogene in GC. Wang et al reported that ELOA promotes cancer progression in cervical cancer, 9 whereas we recently revealed a tumor suppressive role of ELOA in CRC 8 . These studies suggested that ELOA exerts different functions in different cancer types, and the potential mechanisms explaining the variable roles of ELOA in different cancers should be further elucidated.…”

Section: Discussionmentioning

confidence: 60%

“…We previously revealed that ELOA transcriptionally activates LHPP expression and inhibits tumorigenesis and metastasis in colorectal cancer (CRC) 8 . Interestingly, a recent study reported that ELOA promotes the progression of cervical cancer 9 . However, whether and how ELOA affects tumorigenesis in GC remains to be elucidated.…”

Section: Introductionmentioning

confidence: 99%

ELOA promotes tumor growth and metastasis by activating RBP1 in gastric cancer

Tian,

Gong,

Hao

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

BackgroundElongin A (ELOA), our previous work revealed, serves as a novel tumor suppressor in colorectal cancer. However, the function and mechanism of ELOA in other cancer types, including gastric cancer (GC), remain to be elucidated.MethodsThe expression of ELOA was measured by quantitative reverse transcription‐polymerase chain reaction and western blot. The effects of ELOA on GC growth and metastasis were assessed through a series of in‐vitro and in‐vivo assays. Furthermore, the potential mechanism of ELOA was revealed by RNA sequencing, dual luciferase reporter assay, chromatin immunoprecipitation, and rescue experiments in GC.ResultsWe uncovered increased expression of ELOA in GC tissues compared with paired normal tissues via bioinformatic analyses and our sample detection. Enhanced ELOA expression in GC tissues was obviously correlated with poor tumor differentiation, lymph node metastasis, advanced tumor stage, and a poor prognosis. A series of functional experiments showed that ELOA promoted the proliferation and metastasis of GC. Mechanistically, we revealed that the decreased levels of miR‐490‐3p caused the upregulation of ELOA in GC. Both RNA‐seq and ChIP assays revealed that ELOA transcriptionally activated retinol‐binding protein 1 (RBP1) by binding to its promotor. Furthermore, specific knockdown of RBP1 reduced the tumor‐promoting ability of ELOA in GC cells.ConclusionsIn summary, our findings demonstrate that ELOA exerts oncogenic properties by activating RBP1 expression, providing the basis for a promising therapeutic target in GC.

show abstract

“…A549) Kong et al ( 2015 ) Down BLCA tissues and four cell lines (i.a. T24) Yuan et al ( 2021 ) Down BRCA tissues stage I-IV Dou et al ( 2021 ) Down BRCA tissues, MCF-7 (ER + ) and MDA-MB-453 (HER2 + ) Zhou et al ( 2019 ) Down HCC tissues Gao et al ( 2021b ) Down CeCa tissues Wang et al ( 2022a ) Down CeCa tissues Wang et al ( 2021g ) Down OVCA tissues Qiao et al ( 2021 ) † , ‡ For description see footnote to Table 2 …”

Section: Mirnas Targeting Tyms Mrnamentioning

confidence: 99%

MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy

Matuszyk

2022

Mol Med

View full text Add to dashboard Cite

Background The active metabolite of 5-Fluorouracil (5FU), used in the treatment of several types of cancer, acts by inhibiting the thymidylate synthase encoded by the TYMS gene, which catalyzes the rate-limiting step in DNA replication. The major failure of 5FU-based cancer therapy is the development of drug resistance. High levels of TYMS-encoded protein in cancerous tissues are predictive of poor response to 5FU treatment. Expression of TYMS is regulated by various mechanisms, including involving non-coding RNAs, both miRNAs and long non-coding RNAs (lncRNAs). Aim To delineate the miRNAs and lncRNAs network regulating the level of TYMS-encoded protein. Main body Several miRNAs targeting TYMS mRNA have been identified in colon cancers, the levels of which can be regulated to varying degrees by lncRNAs. Due to their regulation by the MALAT1 lncRNA, these miRNAs can be divided into three groups: (1) miR-197-3p, miR-203a-3p, miR-375-3p which are downregulated by MALAT1 as confirmed experimentally and the levels of these miRNAs are actually reduced in colon and gastric cancers; (2) miR-140-3p, miR-330-3p that could potentially interact with MALAT1, but not yet supported by experimental results; (3) miR-192-5p, miR-215-5p whose seed sequences do not recognize complementary response elements within MALAT1. Considering the putative MALAT1-miRNAs interaction network, attention is drawn to the potential positive feedback loop causing increased expression of MALAT1 in colon cancer and hepatocellular carcinoma, where YAP1 acts as a transcriptional co-factor which, by binding to the TCF4 transcription factor/ β-catenin complex, may increase the activation of the MALAT1 gene whereas the MALAT1 lncRNA can inhibit miR-375-3p which in turn targets YAP1 mRNA. Conclusion The network of non-coding RNAs may reduce the sensitivity of cancer cells to 5FU treatment by upregulating the level of thymidylate synthase.

show abstract

TCEB3 is Regulated by Circ-0000212/miR-140-3p Axis to Promote the Progression of Cervical Cancer

Cited by 9 publications

References 43 publications

Circular RNA circ_0000212 accelerates cervical cancer progression by acting as a miR-625-5p sponge to upregulate PTP4A1

Circular RNA circ_0000212 accelerates cervical cancer progression by acting as a miR-625-5p sponge to upregulate PTP4A1

ELOA promotes tumor growth and metastasis by activating RBP1 in gastric cancer

MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy

Contact Info

Product

Resources

About